Status and phase
Conditions
Treatments
About
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Body mass index (BMI) meeting one of the following requirements:
Have a stable body weight (<5% self-reported change during the previous 8 weeks) before screening
Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Charmagne G Beckett, MD, MPH, FACP
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal